BCN Biosciences                            

BCN Bioscience has its core focus on the development of novel monoclonal antibodies against endothelial derived drug targets.

BCN has explored multiple mAB against endothelial derived gene targets which affect breast and colon cancer and is currently moving into definitive preclinical studies with B303 as its lead candidate.   

BCN possesses broad experience in the Oncology drug development space, including management from preclinical discovery to in human trials.